04 July, 2017
Taking a broader look brokerage firms' analysts on the street with an expectant view have Opko Health Inc (NASDAQ:OPK) high price target of $19.5 and with a conservative view have low price target of $8.
On Friday, June 30th, Phillip Md Et Al Frost acquired 3,600 shares of Opko Health stock. Its Average True Range (ATR) value figured out at 6.30. The CEO now owns $1,077,815,212 of the stock according to the SEC filing. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The business had revenue of $296.10 million during the quarter, compared to analyst estimates of $313.36 million. The stock was purchased at an average price of $6.97 per share, with a total value of $12,546.00. The stock was purchased at an average price of $6.43 per share, with a total value of $1,286,000.00. Over the last three months, insiders acquired 2,796,600 shares of company stock valued at $19,058,771. (OPK) have 564.48 million outstanding shares now held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders. The 200 SMA is considered so critically important a trend indicator that the event of the 50-day SMA crossing to the downside of the 200-day SMA is referred to as a death cross, signaling a serious bear market in a stock, index or other investment. The biotechnology company reported ($0.06) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.04) by $0.02. Phillip Md Et Al Frost, CEO disclosed the purchase of 1,800 shares of OPK stock. The company's market capitalization is $3.68 billion.
Traders are a little more bearish on Opko Health, Inc. recently as indicated by the motion in short interest.
There has been some buying insider activity on Opko Health, Inc.
03/03/2017 - Opko Health Inc had its "buy" rating reiterated by analysts at Standpoint Research. Opko Health, Inc. The stock's 50-day moving average is $6.59 and its 200-day moving average is $8.10. Equities research analysts expect that Opko Health will post ($0.20) earnings per share for the current year. The company generated a return on equity (ROE) of -2.10%. During the same quarter in the previous year, the firm earned ($0.02) EPS. World Asset Management Inc raised its position in shares of Opko Health by 23.6% in the first quarter. If you are viewing this story on another website, it was illegally copied and republished in violation of U.S. & worldwide copyright and trademark laws. The correct version of this article can be accessed at https://www.themarketsdaily.com/2017/07/03/phillip-md-et-al-frost-purchases-1800-shares-of-opko-health-inc-nasdaqopk-stock.html. Zacks Investment Research downgraded Opko Health from a "hold" rating to a "sell" rating in a research note on Thursday, May 4th. Private Advisor Group LLC now owns 49,521 shares of the biotechnology company's stock valued at $377,000 after buying an additional 10,670 shares during the period. Comerica Bank acquired a new position in shares of Opko Health during the fourth quarter valued at about $117,000.
Piedmont Investment Advisors LLC expanded its ownership by buying 102,063 shares an increase of 173.7% as of 03/31/2017. State Street Corp boosted its stake in shares of Opko Health by 40.3% in the first quarter. Over the past 2 quarters, the stock is down -42.58%, compared with a fall of almost -17.75% for 3 months and about 2.49% for the past 30 days. Opko Health's revenue for the quarter was up 1.8% on a year-over-year basis. As of quarter end Proficio Capital Partners LLC had disposed of a total of 524 shares trimming its stake by 84.8%. Moving averages are used as a strong indicator for technical stock analysis and it helps investors in figuring out where the stock has been and also facilitate in determining where it may be possibly heading.
OPKO Health, Inc., launched on November 18, 1991, is a diversified healthcare company. The diagnostics segment primarily consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.